April 21, 2020
Hemogenyx gets approval and issuance of European Hu-PHEC Patent
Hemogenyx Pharmaceuticals got European Patent Office’s patent entitled Post-Natal Hemogenic Endothelial Cells and their isolation and use.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
April 20, 2020
Novartis picks up with Phase 3 testing hydroxycholoquine on COVID-19 disease patients
Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease. The clinical trial drug supply will be provided by Sandoz, the generics and biosimilars division of Novartis.
April 20, 2020
USA and European drug-making watchdogs accept applications for Roche’s OCREVUS shorter 2-hour infusion time
Roche said Monday that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and the European Medicines Agency (EMA) has validated the application for a two-hour OCREVUS® (ocrelizumab) infusion time, dosed twice yearly for relapsing or primary progressive multiple sclerosis (MS).
April 14, 2020
Sanofi, GSK team up to make vaccine for COVID-19
Sanofi and GSK today announced teaming up to work on a vaccine for COVID-19, as Sanofi will contribute its S-protein COVID-19 antigen, and GSK contributing pandemic adjuvant technology.
April 9, 2020
Tiziana makes investigational new technology to treat COVID-19 infections
Tiziana Life Sciences said Thursday it has developed investigational new technology to treat COVID-19 infections.
April 8, 2020
Dynavax steps in with Hepatitis B vaccines
Dynavax Technologies Corporation said Wednesday it is donating 10,000 doses of HEPLISAV-B adult vaccine to help protect healthcare professionals on the front lines of the COVID-19 response against hepatitis B.
April 8, 2020
GSK to make an equity investment of $250 million in Vir Biotechnology to tackle COVID-19
GlaxoSmithKline and Vir Biotechnology have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19, in which GSK will make an equity investment in Vir of $250 million, to gain access to Vir’s technology.
April 8, 2020
Oxford Biomedica joins a team working on COVID-19 vaccine candidate
Oxford Biomedica said Wednesday it has joined a Consortium lead by the Jenner Institute, Oxford University, to work on a potential vaccine candidate for COVID-19, called ChAdOx1 nCov-19.
April 8, 2020
Pacific Biosciences of California on COVID-19 update
Pacific Biosciences of California is working with commercial, academic and government research teams that are investigating SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic.